BR9912243A - Formulações de fsh e variantes de fsh, produtos e processos - Google Patents

Formulações de fsh e variantes de fsh, produtos e processos

Info

Publication number
BR9912243A
BR9912243A BR9912243-0A BR9912243A BR9912243A BR 9912243 A BR9912243 A BR 9912243A BR 9912243 A BR9912243 A BR 9912243A BR 9912243 A BR9912243 A BR 9912243A
Authority
BR
Brazil
Prior art keywords
fsh
products
formulations
variants
processes
Prior art date
Application number
BR9912243-0A
Other languages
English (en)
Inventor
James Arthur Hoffmann
Jirong Lu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27536687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9912243(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9912243A publication Critical patent/BR9912243A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçõES DE FSH E VARIANTES DE FSH, PRODUTOS E PROCESSOS"<D>. Esta invenção refere-se a FSH ou variante de FSH contendo uma subunidade alfa e beta contida em formulações, e a artigos de fabricação. A invenção provê novas proteínas vantajosas e ácidos nucléicos, soluções farmacêuticas de múltiplos usos, formulações e produtos de referidas proteínas e ácidos nucléicos, em que nenhum destes aprovados para uso comercial existia anteriormente apresentando as indicações de uso prolongados. Estes produtos são particularmente utilizáveis em regimes terapêuticos para aumentar níveis no soro de FSH ou variante de FSH durante um período de tratamento. Assim, inter alia, a invenção preenche a necessidade para produtos convenientes de FSH ou variante de FSH.
BR9912243-0A 1998-07-23 1999-07-15 Formulações de fsh e variantes de fsh, produtos e processos BR9912243A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9390698P 1998-07-23 1998-07-23
US9461198P 1998-07-30 1998-07-30
US9476798P 1998-07-31 1998-07-31
US9871198P 1998-09-01 1998-09-01
US10069698P 1998-09-17 1998-09-17
PCT/US1999/016031 WO2000004913A1 (en) 1998-07-23 1999-07-15 Fsh and fsh variant formulations, products and methods

Publications (1)

Publication Number Publication Date
BR9912243A true BR9912243A (pt) 2001-10-16

Family

ID=27536687

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912243-0A BR9912243A (pt) 1998-07-23 1999-07-15 Formulações de fsh e variantes de fsh, produtos e processos

Country Status (24)

Country Link
EP (2) EP0974359B2 (pt)
JP (1) JP4719357B2 (pt)
KR (1) KR20010083126A (pt)
CN (1) CN1309567A (pt)
AR (1) AR020618A1 (pt)
AT (2) ATE228850T1 (pt)
AU (1) AU776823B2 (pt)
BR (1) BR9912243A (pt)
CA (1) CA2335340C (pt)
CO (1) CO5090905A1 (pt)
DE (2) DE69928296T2 (pt)
DK (1) DK0974359T4 (pt)
ES (2) ES2250290T3 (pt)
HK (1) HK1026615A1 (pt)
ID (1) ID28747A (pt)
IL (1) IL140984A0 (pt)
MY (1) MY135913A (pt)
NO (1) NO20010326L (pt)
NZ (1) NZ508874A (pt)
PE (1) PE20000939A1 (pt)
PL (1) PL346127A1 (pt)
PT (1) PT974359E (pt)
SI (1) SI0974359T1 (pt)
WO (1) WO2000004913A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414123B1 (en) * 1997-10-21 2002-07-02 Vitro Diagnostics, Inc. Method for purifying FSH
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US7112341B1 (en) 1999-04-13 2006-09-26 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
TWI318100B (en) 2001-03-01 2009-12-11 Lonza Ag Preservative blends containing quaternary ammonium compounds
AR043972A1 (es) 2003-04-02 2005-08-17 Ares Trading Sa Formulaciones farmaceuticas de fsh y lh
PT1638595E (pt) 2003-06-20 2013-04-26 Ares Trading Sa Fsh liofilizada / formulações de hl
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
NZ579740A (en) * 2007-02-08 2011-12-22 Aspenbio Pharma Inc Compositions and methods including expression and bioactivity of bovine follicle stimulating hormone
AU2008267138B9 (en) 2007-06-28 2014-06-05 Theramex HQ UK Limited FSH producing cell clone
MX2010004639A (es) * 2007-11-01 2010-08-04 Merck Serono Sa Formulaciones liquidas de hormona luteinizante (lh).
ES2372470T3 (es) 2008-02-08 2012-01-20 Biogenerix Ag Formulación líquida de fsh.
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
DK2445552T3 (da) 2009-06-24 2016-01-25 Tecpharma Licensing Ag Indgivelsesapparat med klargøringsfunktion
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
WO2011076281A1 (de) 2009-12-23 2011-06-30 Tecpharma Licensing Ag Entfernen einer nadelschutzkappe von einer nadel
WO2011076280A1 (de) 2009-12-23 2011-06-30 Tecpharma Licensing Ag Injektionsvorrichtung mit einer nadelschutzhülse
DK2534650T3 (en) 2010-02-11 2016-09-26 Finox Ag Injection Training Manikin
WO2011099036A2 (en) * 2010-02-12 2011-08-18 Intas Biopharmaceuticals Limited Liquid formulation of follicle stimulating hormone
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012142961A1 (zh) * 2011-04-22 2012-10-26 上海天伟生物制药有限公司 一种低溶剂残留的糖蛋白组合物及其制备方法和用途
JP5750471B2 (ja) * 2013-05-22 2015-07-22 Ｊｃｒファーマ株式会社 組換え体ヒトｆｓｈの製造方法
CN103539861B (zh) * 2013-11-01 2015-02-18 广州联康生物科技有限公司 长效重组人促卵泡激素融合蛋白
CN103554269B (zh) * 2013-11-01 2015-02-11 广州联康生物科技有限公司 重组猪促卵泡激素融合蛋白
CN103539860B (zh) * 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
EP3068374A1 (en) * 2013-11-12 2016-09-21 Cadila Healthcare Limited Formulation for gonadotropins
MX2018002921A (es) * 2015-09-17 2018-12-10 Glycotope Gmbh Composicion de hormona foliculo-estimulante mamifera con estabilidad incrementada.
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839300A (en) * 1957-09-05 1960-06-29 Organon Labor Ltd Adrenocorticotropic hormone preparations and process for making same
US4659696A (en) † 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US5162306A (en) * 1987-01-23 1992-11-10 Donaldson Lloyd E Composition and method for producing superovulation in mammals
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
FR2623715B1 (fr) * 1987-11-26 1990-12-21 Lafon Labor Structures peptidiques, immunogenes les contenant et leurs applications au controle de la fertilite
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
MD1699F2 (ro) * 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
EP0668073B1 (en) † 1994-02-21 1999-04-14 Takeda Chemical Industries, Ltd. Polyester matrix for a pharmaceutical sustained-release preparation
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CA2234231C (en) * 1995-11-07 2009-04-14 Genentech, Inc. Stabilizing formulation for ngf
GB2317010A (en) * 1996-09-04 1998-03-11 Eev Ltd Gas sensor detecting only non-reflected light
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US6287587B2 (en) † 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
ZA9811127B (en) * 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
JP2000151148A (ja) * 1998-11-13 2000-05-30 Mitsumi Electric Co Ltd 携帯用電子機器のコード接続構造

Also Published As

Publication number Publication date
DE69928296T2 (de) 2006-07-27
NO20010326D0 (no) 2001-01-19
EP0974359B1 (en) 2002-12-04
EP1188444A1 (en) 2002-03-20
ID28747A (id) 2001-06-28
ATE228850T1 (de) 2002-12-15
ES2183486T3 (es) 2003-03-16
AU776823B2 (en) 2004-09-23
EP1188444B1 (en) 2005-11-09
SI0974359T1 (en) 2003-04-30
ES2250290T3 (es) 2006-04-16
KR20010083126A (ko) 2001-08-31
AU4998099A (en) 2000-02-14
DE69904262T2 (de) 2003-07-24
CN1309567A (zh) 2001-08-22
JP2002521342A (ja) 2002-07-16
JP4719357B2 (ja) 2011-07-06
CO5090905A1 (es) 2001-10-30
DK0974359T4 (da) 2009-06-29
EP0974359A2 (en) 2000-01-26
CA2335340C (en) 2013-03-05
NO20010326L (no) 2001-03-20
HK1026615A1 (en) 2000-12-22
AR020618A1 (es) 2002-05-22
PT974359E (pt) 2003-02-28
PL346127A1 (en) 2002-01-28
DE69904262T3 (de) 2009-08-13
EP0974359A3 (en) 2001-02-07
DE69928296D1 (de) 2005-12-15
MY135913A (en) 2008-07-31
IL140984A0 (en) 2002-02-10
PE20000939A1 (es) 2000-09-20
CA2335340A1 (en) 2000-02-03
DK0974359T3 (da) 2003-03-03
NZ508874A (en) 2004-03-26
DE69904262D1 (de) 2003-01-16
EP0974359B2 (en) 2009-04-22
ATE308990T1 (de) 2005-11-15
WO2000004913A1 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
BR9912243A (pt) Formulações de fsh e variantes de fsh, produtos e processos
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
BR0112101A (pt) Interleucina 2 estabilizada
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
BR0011433A (pt) Imidazoquinolinas substituìdas com sulfonamida e sulfamida
NO20003286L (no) 11&lt;beta&gt;-halogen-7&lt;alfa&gt;-substituerte østratriener, fremgangsmÕte for fremstilling av farmasøytiske preparater som inneholder disse 11&lt;beta&gt;-halogen-7&lt;alfa&gt;-substituerte østratriener, samt anvendelse av disse for fremstilling av legemidler
DK552684D0 (da) Desulfatohirudiner samt deres fremstilling og anvendelse
DK431887A (da) Dna-forbindelse samt tpa-lignende protein
BR0312276A (pt) Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
BR0010721A (pt) Composições de neisserias combinadas
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
IL142728A0 (en) The use of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
BR9906920A (pt) &#34;tts contendo um antioxidante&#34;
ES2175023T3 (es) Composiciones nutricionales en varias formas.
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
NO20031159D0 (no) Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
ES2159820T3 (es) Dispositivo de acondicionamiento y de aplicacion de un producto capilar.
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
BRPI9910024B8 (pt) uso de uma mistura de alcoóis de açúcar contendo 6-o-alfa-d-glicopiranosil-d-sorbitol (1,6-gps) e 1-o-alfa-d-glicopiranosil-d-manitol (1,1-gpm) in vitro, e composição farmacêutica para consumo humano ou animal
BR9611846A (pt) Artigos de chocolate
AU1971988A (en) Pharmaceutical compositions for the treatment of uraemia
BR9916893A (pt) Tratamento
DK0630651T3 (da) Halvfast farmaceutisk middel og fremgangsmåde til fremstilling heraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.